Plasma metabolomic profile in fibrosing pulmonary sarcoidosis

Mehdi Mirsaeidi, Mohammad Mehdi Banoei, Caleb K. Nienow, Taimur Abassi, Anoushirvan Hakim, Dean Schraufnagel, Brent W. Winston, Nadera Sweiss, Robert Baughman, Joe G N Garcia, Roberto Machado

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: There is no known marker to screen patients with sarcoidosis to determine the risk of progression to pulmonary fibrosis. We aimed to identify potential noninvasive biomarkers for early detection of pulmonary fibrosing sarcoidosis. Methods: A case-control study was performed on African Americans with confirmed sarcoidosis included 31 subjects with pulmonary fibrosis vs. 36 without pulmonary fibrosis. Plasma samples were analyzed by liquid chromatography-mass spectrum. Multivariate statistical analysis models were developed in a training set based on 50 age- And sex-matched samples to identify metabolites involved in the discrimination. Principal component analysis and orthogonal partial least squares-discriminant (OPLS) analysis coupled to the most influential variables were used to derive significant metabolic discriminations. Results: Of the datasets from 171 feature peaks, 14 features including p-coumaroylagmatine and palmitoylcarnitine showed significant differences between fibrosing and non-fibrosing pulmonary sarcoidosis (p = 0.001). OPLS analysis presented clear separation between two groups with an acceptable goodness of fit (R2 = 0.522) and predictive power (Q2=0.322). Discriminating metabolites involved collagen pathway metabolites especially those in the arginine-proline pathway. Conclusions: Metabolomics can provide a useful tool to detect pulmonary fibrosis in patients with sarcoidosis. Two discriminating metabolites, p-coumaroylagmatine and palmitoylcarnitine may be potential markers for fibrosing pulmonary sarcoidosis. (Sarcoidosis Vasc Diffuse Lung Dis 2016; 33: 29-38).

Original languageEnglish (US)
Pages (from-to)29-38
Number of pages10
JournalSarcoidosis Vasculitis and Diffuse Lung Diseases
Volume33
Issue number1
StatePublished - 2016
Externally publishedYes

Fingerprint

Pulmonary Sarcoidosis
Metabolomics
Pulmonary Fibrosis
Sarcoidosis
Palmitoylcarnitine
Discriminant Analysis
Least-Squares Analysis
Statistical Models
Principal Component Analysis
Proline
Liquid Chromatography
African Americans
Arginine
Case-Control Studies
Collagen
Multivariate Analysis
Biomarkers
Lung

Keywords

  • Fibrosis
  • Metabolomics
  • Sarcoidosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Internal Medicine

Cite this

Mirsaeidi, M., Banoei, M. M., Nienow, C. K., Abassi, T., Hakim, A., Schraufnagel, D., ... Machado, R. (2016). Plasma metabolomic profile in fibrosing pulmonary sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 33(1), 29-38.

Plasma metabolomic profile in fibrosing pulmonary sarcoidosis. / Mirsaeidi, Mehdi; Banoei, Mohammad Mehdi; Nienow, Caleb K.; Abassi, Taimur; Hakim, Anoushirvan; Schraufnagel, Dean; Winston, Brent W.; Sweiss, Nadera; Baughman, Robert; Garcia, Joe G N; Machado, Roberto.

In: Sarcoidosis Vasculitis and Diffuse Lung Diseases, Vol. 33, No. 1, 2016, p. 29-38.

Research output: Contribution to journalArticle

Mirsaeidi, M, Banoei, MM, Nienow, CK, Abassi, T, Hakim, A, Schraufnagel, D, Winston, BW, Sweiss, N, Baughman, R, Garcia, JGN & Machado, R 2016, 'Plasma metabolomic profile in fibrosing pulmonary sarcoidosis', Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 33, no. 1, pp. 29-38.
Mirsaeidi M, Banoei MM, Nienow CK, Abassi T, Hakim A, Schraufnagel D et al. Plasma metabolomic profile in fibrosing pulmonary sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2016;33(1):29-38.
Mirsaeidi, Mehdi ; Banoei, Mohammad Mehdi ; Nienow, Caleb K. ; Abassi, Taimur ; Hakim, Anoushirvan ; Schraufnagel, Dean ; Winston, Brent W. ; Sweiss, Nadera ; Baughman, Robert ; Garcia, Joe G N ; Machado, Roberto. / Plasma metabolomic profile in fibrosing pulmonary sarcoidosis. In: Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2016 ; Vol. 33, No. 1. pp. 29-38.
@article{26069344ea77470b914f6ed8d895ce74,
title = "Plasma metabolomic profile in fibrosing pulmonary sarcoidosis",
abstract = "Background: There is no known marker to screen patients with sarcoidosis to determine the risk of progression to pulmonary fibrosis. We aimed to identify potential noninvasive biomarkers for early detection of pulmonary fibrosing sarcoidosis. Methods: A case-control study was performed on African Americans with confirmed sarcoidosis included 31 subjects with pulmonary fibrosis vs. 36 without pulmonary fibrosis. Plasma samples were analyzed by liquid chromatography-mass spectrum. Multivariate statistical analysis models were developed in a training set based on 50 age- And sex-matched samples to identify metabolites involved in the discrimination. Principal component analysis and orthogonal partial least squares-discriminant (OPLS) analysis coupled to the most influential variables were used to derive significant metabolic discriminations. Results: Of the datasets from 171 feature peaks, 14 features including p-coumaroylagmatine and palmitoylcarnitine showed significant differences between fibrosing and non-fibrosing pulmonary sarcoidosis (p = 0.001). OPLS analysis presented clear separation between two groups with an acceptable goodness of fit (R2 = 0.522) and predictive power (Q2=0.322). Discriminating metabolites involved collagen pathway metabolites especially those in the arginine-proline pathway. Conclusions: Metabolomics can provide a useful tool to detect pulmonary fibrosis in patients with sarcoidosis. Two discriminating metabolites, p-coumaroylagmatine and palmitoylcarnitine may be potential markers for fibrosing pulmonary sarcoidosis. (Sarcoidosis Vasc Diffuse Lung Dis 2016; 33: 29-38).",
keywords = "Fibrosis, Metabolomics, Sarcoidosis",
author = "Mehdi Mirsaeidi and Banoei, {Mohammad Mehdi} and Nienow, {Caleb K.} and Taimur Abassi and Anoushirvan Hakim and Dean Schraufnagel and Winston, {Brent W.} and Nadera Sweiss and Robert Baughman and Garcia, {Joe G N} and Roberto Machado",
year = "2016",
language = "English (US)",
volume = "33",
pages = "29--38",
journal = "Sarcoidosis Vasculitis and Diffuse Lung Diseases",
issn = "1124-0490",
publisher = "Mattioli 1885 S.p.A.",
number = "1",

}

TY - JOUR

T1 - Plasma metabolomic profile in fibrosing pulmonary sarcoidosis

AU - Mirsaeidi, Mehdi

AU - Banoei, Mohammad Mehdi

AU - Nienow, Caleb K.

AU - Abassi, Taimur

AU - Hakim, Anoushirvan

AU - Schraufnagel, Dean

AU - Winston, Brent W.

AU - Sweiss, Nadera

AU - Baughman, Robert

AU - Garcia, Joe G N

AU - Machado, Roberto

PY - 2016

Y1 - 2016

N2 - Background: There is no known marker to screen patients with sarcoidosis to determine the risk of progression to pulmonary fibrosis. We aimed to identify potential noninvasive biomarkers for early detection of pulmonary fibrosing sarcoidosis. Methods: A case-control study was performed on African Americans with confirmed sarcoidosis included 31 subjects with pulmonary fibrosis vs. 36 without pulmonary fibrosis. Plasma samples were analyzed by liquid chromatography-mass spectrum. Multivariate statistical analysis models were developed in a training set based on 50 age- And sex-matched samples to identify metabolites involved in the discrimination. Principal component analysis and orthogonal partial least squares-discriminant (OPLS) analysis coupled to the most influential variables were used to derive significant metabolic discriminations. Results: Of the datasets from 171 feature peaks, 14 features including p-coumaroylagmatine and palmitoylcarnitine showed significant differences between fibrosing and non-fibrosing pulmonary sarcoidosis (p = 0.001). OPLS analysis presented clear separation between two groups with an acceptable goodness of fit (R2 = 0.522) and predictive power (Q2=0.322). Discriminating metabolites involved collagen pathway metabolites especially those in the arginine-proline pathway. Conclusions: Metabolomics can provide a useful tool to detect pulmonary fibrosis in patients with sarcoidosis. Two discriminating metabolites, p-coumaroylagmatine and palmitoylcarnitine may be potential markers for fibrosing pulmonary sarcoidosis. (Sarcoidosis Vasc Diffuse Lung Dis 2016; 33: 29-38).

AB - Background: There is no known marker to screen patients with sarcoidosis to determine the risk of progression to pulmonary fibrosis. We aimed to identify potential noninvasive biomarkers for early detection of pulmonary fibrosing sarcoidosis. Methods: A case-control study was performed on African Americans with confirmed sarcoidosis included 31 subjects with pulmonary fibrosis vs. 36 without pulmonary fibrosis. Plasma samples were analyzed by liquid chromatography-mass spectrum. Multivariate statistical analysis models were developed in a training set based on 50 age- And sex-matched samples to identify metabolites involved in the discrimination. Principal component analysis and orthogonal partial least squares-discriminant (OPLS) analysis coupled to the most influential variables were used to derive significant metabolic discriminations. Results: Of the datasets from 171 feature peaks, 14 features including p-coumaroylagmatine and palmitoylcarnitine showed significant differences between fibrosing and non-fibrosing pulmonary sarcoidosis (p = 0.001). OPLS analysis presented clear separation between two groups with an acceptable goodness of fit (R2 = 0.522) and predictive power (Q2=0.322). Discriminating metabolites involved collagen pathway metabolites especially those in the arginine-proline pathway. Conclusions: Metabolomics can provide a useful tool to detect pulmonary fibrosis in patients with sarcoidosis. Two discriminating metabolites, p-coumaroylagmatine and palmitoylcarnitine may be potential markers for fibrosing pulmonary sarcoidosis. (Sarcoidosis Vasc Diffuse Lung Dis 2016; 33: 29-38).

KW - Fibrosis

KW - Metabolomics

KW - Sarcoidosis

UR - http://www.scopus.com/inward/record.url?scp=84963964179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963964179&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 29

EP - 38

JO - Sarcoidosis Vasculitis and Diffuse Lung Diseases

JF - Sarcoidosis Vasculitis and Diffuse Lung Diseases

SN - 1124-0490

IS - 1

ER -